The Deep Oceans as a Source for New Treatments for Cancer
The development of new approaches for the treatment of cancer represents one of the greatest challenges of modern-day science. Beginning in the mid-1970s with the passage of the “National Cancer Act” and the establishment of the American National Institutes of Health’s National Cancer Institute (NCI), a worldwide effort was undertaken to discover and develop new treatments for this devastating disease. Not surprisingly, one of the most important approaches to this problem was the discovery of new anticancer drugs from natural sources. Programs were developed at NCI to access new plant species from common and remote environments throughout the world, resulting in the discovery of a significant number of lead molecules, such as taxol, that ultimately became part of a primary arsenal of drugs to treat this disease. Although the ocean is 70% of the Earth’s surface and 95% of its crust, this source was not examined until later. A major effort was undertaken by NCI to collect, extract, and assay a massive number of marine plants and animals. The results were impressive, and this achievement underscored the effort to pursue marine organisms. As of 2011, more than 20 marine-derived compounds are in clinical trials for various cancers, and two drugs Yondelis®(aka Trabectedin) and Havalen®(aka Eribulin Mesylate) are currently on the market for treatment of numerous cancer subtypes .
KeywordsAcademic Entrepreneurism Human Colon Carcinoma Cell Line Confocal Microscopic Examination American National Institute Mass Spectrometric Protein
In this review, I have briefly outlined a large amount of research ongoing in my laboratory. These studies have been supported by the National Institutes of Health, National Cancer Institute under grant R37 044848.
- 3.Jensen PR, Fenical W (2007) Marine actinomycete bacteria, developing a new resource for drug discovery. Nat Chem Biol 2:666–673Google Scholar
- 13.Alexander MD, Burkart MD, Leonard MS, Portonovo P, Liang B, Ding X, Joullie MM, Gulledge BM, Aggen JB, Chamberlin AR, Sandler J, Fenical W, Cui J, Gharpure SJ, Polosukhin A, Zhang H, Evans PA, Richardson AD, Harper MK, Ireland CM, Vong BG, Brady TP, Theodorakis EA, La Clair JJ (2006) A central strategy for converting natural products into fluorescent probes. Chembiochem 7:409–416PubMedCrossRefGoogle Scholar
- 19.Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC (2011) A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood 117:5692–5700, See also: http://www.empr.com/phase-2-trial-of-plinabulin-npi-2358-for-the-treatment-of-advanced-non-small-cell-lung-cancer-nsclc/article/158324/ PubMedCrossRefGoogle Scholar